Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06287775 · ClinicalTrials.gov registry record · Phase 1

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

A Phase 1 study of Stage IV Lung Cancer AJCC v8 and Extensive Stage Lung Small Cell Carcinoma, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 1
Development phase
45
Enrollment target
20
Study locations

NCT06287775 is a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Extensive Stage Lung Small Cell Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06287775, a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Extensive Stage Lung Small Cell Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
20
Study locations

Study Summary

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.

Conditions Studied

Stage IV Lung Cancer AJCC v8 Extensive Stage Lung Small Cell Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • BIOLOGICAL Atezolizumab
  • PROCEDURE Biopsy Procedure
  • BIOLOGICAL Durvalumab

Study Locations (20)

Connecticut

  • Smilow Cancer Hospital Care Center at Saint Francis - Hartford
  • Yale University - New Haven
  • Yale-New Haven Hospital North Haven Medical Center - North Haven
  • Smilow Cancer Hospital Care Center at Long Ridge - Stamford
  • Smilow Cancer Hospital Care Center-Trumbull - Trumbull

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • City of Hope at Irvine Lennar - Irvine
  • UC San Diego Moores Cancer Center - La Jolla
  • University of California Davis Comprehensive Cancer Center - Sacramento

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Hospital/Winship Cancer Institute - Atlanta
  • Emory Saint Joseph's Hospital - Atlanta

Illinois

  • University of Chicago Comprehensive Cancer Center - Chicago
  • UC Comprehensive Cancer Center at Silver Cross - New Lenox
  • University of Chicago Medicine-Orland Park - Orland Park

Florida

  • UF Health Cancer Institute - Gainesville - Gainesville
  • Moffitt Cancer Center - Tampa

District of Columbia

  • MedStar Georgetown University Hospital - Washington D.C.

Indiana

  • UChicago Medicine Northwest Indiana - Crown Point

Kansas

  • University of Kansas Clinical Research Center - Fairway

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2025-04-08
Est. Completion 2029-07-25
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06287775

The ClinicalTrials.gov registry entry for NCT06287775 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (54% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06287775 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Connecticut, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06287775 about?

NCT06287775 is a clinical study titled "Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer". This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts o...

What is the current status of trial NCT06287775?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-04-08. Estimated completion is 2029-07-25.

What conditions does trial NCT06287775 study?

This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Extensive Stage Lung Small Cell Carcinoma.

What interventions are being tested in trial NCT06287775?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Atezolizumab (BIOLOGICAL), Biopsy Procedure (PROCEDURE), Durvalumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06287775?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06287775 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Lung Cancer AJCC v8

All registered trials for this condition

Extensive Stage Lung Small Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.